The Past Three Years for Intellia Therapeutics (NASDAQ:NTLA) Investors Has Not Been Profitable
Every investor on earth makes bad calls sometimes. But really big losses can really drag down an overall portfolio. So spare a thought for the long term shareholders of Intellia Therapeutics, Inc. (
Cathie Wood's Ark Invest Dumps Another $3.25M Worth Of Tesla Shares Amid Searing Q2 Deliveries Rally
On Wednesday, Cathie Wood-led Ark Invest made a notable move by offloading a significant number of shares in Tesla Inc (NASDAQ:TSLA), despite the recent rally driven by the company's impressive second
Intellia Therapeutics(NTLA.US) Officer Sells US$9,286.65 in Common Stock
$Intellia Therapeutics(NTLA.US)$ Officer Clark Eliana sold 405 shares of common stock on Jul 1, 2024 at an average price of $22.93 for a total value of $9,286.65.Source: Announcement What is statement
Cathie Wood's Ark Invest Sells Tesla Shares Worth $14.5M Amid Rally Driven By Q2 Delivery Numbers, Picks Up Palantir Shares Again Today
On Tuesday, Cathie Wood-led Ark Invest made significant adjustments to its portfolio, offloading a substantial number of shares in Tesla Inc (NASDAQ:TSLA) and scooping up a hefty stake in Palantir Tec
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Maintains $73 Price Target
Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $73 price target.
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $24 to $73
On Jun 27, major Wall Street analysts update their ratings for $Intellia Therapeutics(NTLA.US)$, with price targets ranging from $24 to $73.BMO Capital analyst Kostas Biliouris maintains with a buy ra
Cathie Wood's Ark Invest Acquires $7.3M Worth Of Shares In This Promising Netflix Competitor, Sells Off Coinbase Stock Amid Bitcoin Slump
On Wednesday, Cathie Wood-led Ark Invest made significant trades in Roku Inc (NASDAQ:ROKU) and Coinbase Global Inc (NASDAQ:COIN), amidst a volatile market. These prominent trades were part of a series
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $29 to $95
On Jun 26, major Wall Street analysts update their ratings for $Intellia Therapeutics(NTLA.US)$, with price targets ranging from $29 to $95.Citi analyst David Lebovitz maintains with a hold rating, an
Intellia Therapeutics: Dulac Recently Served as CFO of Fate Therapeutics >NTLA
Intellia Therapeutics: Dulac Recently Served as CFO of Fate Therapeutics >NTLA
Express News | Intellia Therapeutics Inc - Glenn Goddard to Step Down as CFO Effective June 30, 2024
Express News | Intellia Therapeutics Inc - Appoints Edward Dulac as CFO Effective July 22, 2024
Express News | Intellia Therapeutics Announces CFO Transition
Intellia Therapeutics Presents Data On Redosing With In Vivo CRISPR Therapy; 55 Mg NTLA-2001 Dose Shows 90% Median Reduction In Serum TTR At Day 28; Well Tolerated Across All Patients; Potential Redosing Advantage For Future Therapies
First-ever clinical data demonstrating redosing with an investigational in vivo CRISPR-based therapyFollow-on dosing with a 55 mg dose of NTLA-2001 led to a 90% median reduction in serum TTR at day 28
Express News | Intellia Therapeutics Inc: 55 Mg Follow-on Dose Was Well Tolerated Across All Patients
Express News | Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy With Its Proprietary Lnp-Based Delivery Platform
Small-cap, Buy-rated Stocks With Positive Estimate Revision Factors - BofA
Truist Financial Maintains Intellia Therapeutics(NTLA.US) With Buy Rating
Truist Financial analyst Joon Lee maintains $Intellia Therapeutics(NTLA.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 46.4% and a total average return of 19.0% o
Morgan Stanley Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $57
Morgan Stanley analyst Terence Flynn maintains $Intellia Therapeutics(NTLA.US)$ with a buy rating, and maintains the target price at $57.According to TipRanks data, the analyst has a success rate of 6
Intellia Therapeutics Price Target Maintained With a $65.00/Share by Cantor Fitzgerald
Intellia Therapeutics Price Target Maintained With a $65.00/Share by Cantor Fitzgerald
Unveiling 6 Analyst Insights On Intellia Therapeutics
Analysts' ratings for Intellia Therapeutics (NASDAQ:NTLA) over the last quarter vary from bullish to bearish, as provided by 6 analysts.The following table summarizes their recent ratings, shedding li